Polycystic ovary syndrome (PCOS) has a new name. On May 12, 2026, The Lancet published a global consensus renaming it polyendocrine metabolic ovarian syndrome (PMOS). The change ends decades of confusion over a term that never described the condition well.

The work came from 56 academic, clinical, and patient organizations. Iterative global surveys drew more than 14,300 responses from people with the condition and health professionals across every world region. The authors set clear priorities for the new name: scientific accuracy, clarity, stigma avoidance, cultural fit, and practical adoption.

Clinicians and patients flagged the problem for years. The word "polycystic" points to ovarian cysts, but the condition does not produce them. The structures seen on ultrasound are arrested follicles, not cysts.

The mislabel carried real cost. It obscured the hormonal and metabolic features at the core of the condition, delayed diagnosis for as many as 70% of patients, fragmented care, and fed stigma. It also narrowed how researchers and policymakers framed the disease.

Each word in polyendocrine metabolic ovarian syndrome carries clinical meaning.

The authors set a three-year managed transition, built on an eight-stage implementation plan co-designed with patients, marketing and implementation experts, and governance bodies. The stages run from academic publication through resource development, global communication, and formal adoption.

A name that reflects the hormonal and metabolic reality of the condition helps clinicians frame diagnosis and counseling around the whole patient, not the ovary alone. The authors expect the shift to raise awareness, speed diagnosis, improve care quality and patient satisfaction, and sharpen outcomes across the full range of features. An embedded evaluation strategy will track those goals through the transition.